1. InspireMD inks Chile distribution deal
InspireMD announced in an Oct. 12 press release that it has signed a distribution deal with CorpMedical Chile to distribute the MGuard Prime Embolic Protection System (EPS). The MGuard Prime EPS treats acute coronary syndromes like acute myocardial infarctions.
2. Medacta launches MiniMed hip stem
Medacta has launched its MiniMAX Hip System in the U.S., according to an Oct. 12 press release. MiniMAX is an anatomical cementless stem that is engineered to provide enhanced fit and fill in the metaphyseal femur. It follows the natural shape of the femoral canal for minimally-invasive anterior and posterior hip replacement procedures.
3. Esaote launches MyLab 9 ultrasound
Esaote announced in an Oct. 13 press release that it has launched its MyLab 9 ultrasound platform. MyLab 9 has smart upgradability, remote serviceability, long-term maintenance options and transducer compatibility.
4. Subchondral system wins FDA nod for orthopedic screw system
Subchondral Solutions has received FDA 510(k) clearance for its S4 Screw System, according to a Sept. 29 press release. The S4 Screw System is a fenestrated cannulated screw set that is designed for osteochondral fractures of the joint. The clearance allows for the company to begin commercializing its products in the U.S.
5. Hill-Rom’s Welch Allyn, Honeywell ink remote patient monitoring deal
Welch Allyn announced in an Oct. 10 press release that its home medical devices are being offered with Honeywell’s remote patient monitoring platform. Welch Allyn Home 1700 Series Blood Pressure Monitor with SureBP technology and Welch Allyn Home Weight Scale are set to be offered as standard peripherals with Honeywell’s Genesis Touch remote patient monitoring kits. Genesis Touch uses Android tablets to a consumer-based, connected interface. Welch Allyn devices will pair wirelessly with Honeywell’s remote patient monitoring platform.
6. VivaSure launches PerQSeal study
VivaSure has enrolled its first patient in its Frontier IV clinical study, according to an Oct. 13 press release. The study is designed to expand the indications of its PerQseal large arteriotomy closure technology. PerQseal is the world’s first fully absorbable, patch-based large-bore percutaneous closure technology.
7. RenalGuard touts study
RenalGuard announced in an Oct. 12 press release the results of its study testing the feasibility and safety of RenalGuard use in reducing the risk of cardiac surgery-associated acute kidney injury (AKI). Patients who were having cardiopulmonary bypass surgery had an increased risk of developing AKI. RenalGuard Therapy was administered to the patients prior to surgery and was continued for six to 12 hours after the patient was transferred to the cardiac intensive care unit. None of the patients developed AKI in the 36 hours after surgery. One patient did develop cardiac tamponade eight hours after surgery and one patient developed paralytic ileus. Another patient was electively hemofiltered on day 3 after having acute right ventricular failure while one patient had a stroke one week after surgery. The study suggests that these events were not related to the RenalGuard system.
